Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of [14C]Ulonivirine in Healthy Adults
NCT07334886Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ulonivirine in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Cumulative Percentage of Total Radioactivity Recovered from Urine and Feces at 5 weeks, Cumulative Percentage of Total Radioactivity Recovered from Urine at 5 weeks and 5 more. Started Sep 2025; status: completed.
02
Drugs
ulonivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07334886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07334886.